LSD-based treatment shows promise for generalized anxiety disorder in late-stage trial
Definium Therapeutics announced that its LSD therapy significantly reduced anxiety in patients with generalized anxiety disorder in a late-stage clinical trial. This is the first of two large trials. The results suggest potential new treatment options for anxiety disorders.
Related stories
Definium Therapeutics' oral LSD candidate succeeds in initial Phase 3 trial for generalized anxiety disorder · Mental health
Eyepoint's wet AMD therapy misses key endpoint in trial · Drug development
Sugar Restriction in Infancy Tied to Lower Cancer Risk; Melanoma Vaccine Shows Promise · Cancer research
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial.” Browse more stories.